Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
R.M. Chidiac, D.C. Aron.
Incidentalomas. A disease of modern technology.
Endocrinol Metab Clin North Am, 26 (1997), pp. 233-253
[2.]
G.T. Griffing.
Editorial: A.I.D.S. the new endocrine epidemic.
J Clin Endocrinol Metab, 79 (1994), pp. 1530-1531
[3.]
D.A. Linos.
Management approaches to suprarrenal incidentalomas (suprarrenalomas). A view from Athenas, Greece.
Endocrinol Metab Clin North Am, 29 (2000), pp. 141-157
[4.]
B.S. Lewinsky, K.M. Grigor, T. Symington, A.M. Neville.
The clinical and pathologic features of “non-hormonal” adrenocortical tumors.
Cancer, 33 (1974), pp. 778-790
[5.]
H.S. Glazer, P.J. Weyman, S.S. Sagel, R.G. Levitt, B.L. McClennam.
Nonfunctioning suprarrenal masses: incidental discovery on computed tomography.
Am J Roentgenol, 139 (1982), pp. 81-85
[6.]
P.M. Copeland.
The incidentally discovered suprarrenal mass.
Ann Intern Med, 98 (1983), pp. 940-945
[7.]
M.F. Herrera, C.S. Grant, J.A. Van Heerden, P.F. Sheedy II, D.M. Ilstrup.
Incidentally discovered suprarrenal tumors: an institutional perspetive.
Surgery, 110 (1991), pp. 1014-1021
[8.]
A. Belldegrun, S. Hussain, S.E. Seltzer, K.R. Loughlin, R.F. Gittes, J.P. Ricchie.
Incidentally discovered mass of the suprarrenal gland.
Surg Gynecol Obstet, 163 (1986), pp. 203-208
[9.]
H. Hedeland, G. Ostered, B. Hokfelt.
On the prevalence of adrenorcortical adenomas in autopsy material in relation to hypertension and diabetes.
Acta Med Scand, 194 (1968), pp. 211-214
[10.]
M. Abecassis, M.J. McLoughlin, Langer, M. Kudlow.
Serendipitous suprarrenal masses: prevalence, significance, and management.
A J Surg, 139 (1985), pp. 783-788
[11.]
D.M. Cook, D.L. Loriaux.
The incidental suprarrenal mass.
Adv Endocrinol Metab Vol. V, pp. 137-170
[12.]
A. Belldegrun, S. Hussain, S.E. Seltzer, K.R. Loughlin, R.F. Gittes, T. Richie.
Incidentally discovered mass of the suprarrenal gland.
Surg Gynecol Obstet, 163 (1986), pp. 203-208
[13.]
R.T. Kloos, M.D. Gross, I.R. Francis, M. Korobkin, B. Shapiro.
Incidentally discovered suprarrenal masses.
Endocr Rev, 16 (1995), pp. 460-484
[14.]
R.N. Dunnick.
Suprarrenal imaging: current status.
Am J Roentgenol, 154 (1990), pp. 927-936
[15.]
M.D. Gross, B. Shapiro.
Clinically silent suprarrenal masses.
J Clin Endocrinol Metab, 77 (1993), pp. 885-888
[16.]
F. Jockenhouel, W. Kjck, B.W. Hauffa, W. Reinharot, G. Benker, S. Lederbogen, et al.
Consecutive and surgical management of incidentally discovered suprarrenal tumors (incidentalomas.
J Endocrinol Invest, 15 (1992), pp. 331-337
[17.]
D.B. Turton, J.T. O’Brien, M.M. Shakir.
Incidental suprarrenal nodules: association with exagerated 17-hydroxyprogesterone response to adrenocorticotropin hormone.
J Endocrinol Invest, 15 (1992), pp. 789-796
[18.]
B. Ambrosi, S. Peverelly, F. Passins, T. Re, R. Ferrario, P. Colombo.
Abnormalities of endocrine function in patients with clinically “silent” suprarrenal massas.
Eur J Endocrinol, 132 (1995), pp. 422-428
[19.]
M.S. Ross, D.C. Aron.
Hormonal evaluation of the patient with an incidentally discovered suprarrenal mass.
N Engl J Med, 323 (1990), pp. 1402-1405
[20.]
M.J. Young, C. Dmuchowski, J.W. Wallis.
Biochemical tests for pheochromocytoma: strategies in hypertensive patients.
J Gen Intern Med, 4 (1989), pp. 273-276
[21.]
B. Shapiro, L.M. Fig.
Management of pheochromocytoma.
Endocrinol Metab Clin North Am, 18 (1989), pp. 443-481
[22.]
E. Gross, D.S. Goldstein, A. Hoffman.
Glucagon and clonidine testing in the diagnosis of pheochromocytome.
Hypertension, 17 (1991), pp. 275-286
[23.]
B. Charbonell, J.F. Chantal, P. Ozamme.
Does the corticoadrenal adenom with “pre-Cushing’s syndrome” exists?.
J Nucl Med, 22 (1981), pp. 1059-1061
[24.]
H.S. Beyer, R.F. Doe.
Cortical secretion by an incidentally disciveral nonfunctional adrenal adenoma.
J Clin Endocrinol Metab, 62 (1986), pp. 1317-1371
[25.]
J.M. Real Fernández, W. Ricart-Engels, R. Simó, I. Salinas, S.M. Webb.
re-clinical Cushing’s syndrome: report of three cases and literature review.
Horm Res, 41 (1994), pp. 230-235
[26.]
R.H. Caplan, P.J. Strutt, G.C. Wickus.
Subclinical hormone secretion by incidentally discovered suprarrenal mass.
Arch Surg, 129 (1994), pp. 291-296
[27.]
M. Reincke, J. Nieke, N. Krestin, W. Saegor, B. Allolio, W. Wienkelmann.
Preclinical Cushing’s syndrome in suprarrenal “incidentalomas”. Comparison with suprarrenal Cushing’s syndrome.
J Clin Endocrinol Metab, 75 (1992), pp. 826-832
[28.]
W. Oelkers.
Diagnostic puzzle of the suprarrenal “incidentaloma”.
Eur J Endocrinol, 132 (1995), pp. 419-421
[29.]
R. Rossi, L. Tauchmanova, A. Luciano, M. Di Martino, C. Battista, L. Viscovo, et al.
Subclinical Cushing’s syndrome in patients with suprarrenal incidentaloma: clinical and biochemical features.
J Clin Endocrinol Metab, 85 (2000), pp. 1440-1448
[30.]
M. Reincke.
Subclinical Cushing’s syndrome.
Endomicrob Metab Clin North Am, 29 (2000), pp. 43-56
[31.]
G. Olsella, M. Terzolo, G. Reimondo, A. Piovesan, A. Pia, A. Termine, et al.
Serum markers of bone and collagen turnover in patiens with Cushing’s syndrome and in subjects with suprarenal incidentalomas.
J Clin Endocrinol Metab, 82 (1997), pp. 3303-3307
[32.]
N.S. Ross.
Epidemiology of Cushing’s syndrome and clinical disease.
Endocrinol Metab Clin North Am, 26 (1997), pp. 233-253
[33.]
M.K. McLeod, N.W. Thompson, M.D. Gross, A.G. Bondeson, L. Bondeson.
Sub-clinical Cushing syndrome in patients with suprarrenal gland incicentalomas. Pitfalls in diagnosis and management.
Ann Surg, 56 (1990), pp. 398-403
[34.]
M. Terzollo, A. Ali, G. Osella, F. Cesari, A. Paccotti, A. Angeli.
Subclinical Cushing syndrome in suprarrenal incidentaloma.
Clin Endocrinol (Oxf, 48 (1998), pp. 89-97
[35.]
G. Hofle, R.W. Gasser, K. Lhotta, G. Janetschek, A. Kreczy, G. Finkenstedt.
Suprarrenal carcinoma evolving after diagnosis of preclinical Cushing’s syndrome in a suprarrenal incidentaloma.
Horm Res, 50 (1998), pp. 237-242
[36.]
S. Tsagarakis, P. Kokkoris, C. Roboti, C. Malagari, J. Kaskarelis, V. Vlassopoulo, et al.
The low-dose dexamethasone suppresion test in patients with suprarrenal incidentalomas: comparisons with clinically eusuprarrenal subjects and patients with Cushing’s syndrome.
Clin Endocrinol (Oxf, 48 (1998), pp. 627-633
[37.]
S. Tsagarakis, C. Roboti, P. Kokkoris, K. Vasiliou, C. Alevizaki, N. Thalassinos.
Elevated postdexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamopituitary suprarrenal axis in patients with suprarrenal incidentalomas.
Clin Endocrinol (Oxf, 49 (1998), pp. 165-171
[38.]
H. Lavoie, A. Lacroix.
Partially autonomous cortisol secretion by incidentally discovered suprarrenal adenomas.
Trends in endocrinology and metabolism, 6 (1995), pp. 191-197
[39.]
M. Reincke, J. Nieke, G.P. Krestin, W. Saeger, B. Allolio, W. Wienkelmann.
Preclinical Cushing’s syndrome in suprarrenal “incidentalomas”: comparison with suprarrenal Cushing’s syndrome.
J Clin Endocrinol Metab, 75 (1992), pp. 826-832
[40.]
R.M. Chidiac, D.V. Aron.
Incidentalomas: a disease of modern technology.
Endocrinol Metab Clin North Am, 26 (1997), pp. 233-253
[41.]
C.M. Huiras, G.B. Pehling, R.H. Caplan.
Suprarrenal insufficiency after operative removal of apparently nonfunctioning adrenal adenomas.
JAMA, 261 (1989), pp. 894-898
[42.]
G. Osella, M. Terzolo, G. Borreta.
Endocrine evaluation of incidentally discovered suprarrenal masses (incidentalomas.
J Clin Endocrinol Metab, 79 (1994), pp. 1532-1539
[43.]
D. Flecchia, E. Mazza, M. Carlini, A. Blatto, F. Olivieri, G. Serra, et al.
Reduced serum levels of dehydroepiandrosterone sulphate in suprarrenal incidentalomas: a marker of adrenocortical tumour.
Clin Endocrinol (Oxf, 42 (1995), pp. 129-134
[44.]
M. Terzolo, G. Osella, A. Ali, G. Borreta, G.P. Magro, A. Termine, et al.
Different patterns of steroid secretion in patients with suprarrenal incidentaloma.
J Clin Endocrinol Metab, 81 (1996), pp. 740-744
[45.]
Z. Bencik, I. Szabolks, Z. Kovaks, A. Ferencz, A. Voros, I. Kasza, et al.
Low dehydroepiandrosterone sulfate (DHEA-S) level is not a good predictor of hormonal activity in nonselected patients with incidentally detected suprarrenal tumor.
J Clin Endocrinol Metab, 81 (1996), pp. 1726-1729
[46.]
A.N. Margioris, G.P. Chrousos.
Cushing’s syndrome diagnostic evaluation.
Endocrine hypertension, pp. 99-111
[47.]
F. Mantero, M. Terzolo, G. Arnaldi, G. Osella, A.M. Massimi, A. Ali, et al.
A survey on suprarrenal incidentaloma in Italy.
J Clin Endocrinol Metab, 85 (2000), pp. 637-644
[48.]
M. Terzolo, A. Ali, G. Osella, G. Reimondo, A. Pia, P. Peretti, et al.
The value of dehydroepiandrosterone sulfate measurement in the differentiation between and malignan adrenal masses.
Europ J Endroc, 142 (2000), pp. 611-617
[49.]
D.A. Freeman.
Steroid hormone producing tumors of the suprarrenal, ovary and testes.
Endocrinol Metab Clin Noth Am, 20 (1991), pp. 751-766
[50.]
T. Seppel, R. Schlaghecke.
Augmented 17?-hydroxyprogesterone response to ACTH stimulation as evidence of decreased 21-hydroxylase activity in patients with incidentally discovered suprarrenal tumors (“incidentalomas”.
Clin Endocrinol Oxf, 41 (1994), pp. 445-451
[51.]
R.T. Kloos, M.D. Gross, I.R. Francis, M. Korobkin, B. Shapiro.
Incidentally discovered suprarrenal masses.
Endocr Rev, 16 (1995), pp. 460-484
[52.]
K. Racz, F. Pient, T. Marotn, B. Szende, E. Glaz, P. Corvor.
Expression of steroidogenic enzime messenger ribonucleic acids and corticosteroid production in aldosterone-producing ans “nonfunctioning” suprarrenal adenomas.
J Clin Endocrinol Metab, 77 (1993), pp. 677-682
[53.]
J.L. Sadoul, B. Kezachian, S. Altare, Y. Hadjali, B. Canivet.
Apparent activities of 21-hydroxylase, 17??hydroxylase an 17-20 lyase are impaired in suprarrenal incidentalomas.
Eur J Endocrinol, 141 (1999), pp. 238-245
[54.]
R. Del Monte, D. Bernasconi, L. Bertolazzi, M. Meozzi, B. Badaracco, R. Torre, et al.
Increased 17?-hydroxyprogesterone response to ACTH in silient suprarrenal adenoma: cause or effect.
Clin Endocrinol (Oxf, 42 (1995), pp. 273-277
[55.]
G.P. Bernini, G. Brogi, M.S. Vivaldi, G.F. Argenio, N. Sgro, A. Moretti, et al.
17-hydroxyprogesterone response to ACTH in bilateral and monolateral suprarrenal incidentalomas.
J Endocrinol Invest, 19 (1996), pp. 745-752
[56.]
M. Toth, K. Racz, E. Glaz.
Increased plasma 17-hydroxyprogesterone response to ACTH in patients with nonhyperfunctioning suprarrenal adenomas is not due to a deficiency in 21 hydroxylase activity.
J Clin Endocrinol Metab, 83 (1998), pp. 3756-3757
[57.]
T.H. Falke, A.P. Van Seters, A. Schaberg, A.J. Moolenacar.
Computed tomography in untreated adults with virilizing congenital suprarrenal cortical hyperplasia.
Clin Radiol, 37 (1986), pp. 155-160
[58.]
R. Ravichandran, F. Lafferty, M.J. McGinniss, H.C. Taylor.
Congenital suprarrenal hyperplasia present as massive suprarrenal incidentalomas in the sitxh decade of life: report of two patients with 21 hydroxylase deficiency.
J Clin Endocrinol Metab, 81 (1996), pp. 1776-1779
[59.]
S. Jaresch, E. Kornely, H.K. Kley, B. Schlahecke.
Suprarrenal incidentaloma and patients with homozygous or heterogygous congenital suprarrenal hyperplasia.
J Clin Endocrinol Metab, 74 (1992), pp. 685-689
[60.]
J. Hensen, M. Buhl, V. Bähr, W. Oelkers.
Endocrine activity of the “silent” adrenocortical adenoma is uncovered by response to corticotropin releasing-hormone.
Klin Wochenshr, 68 (1990), pp. 608-614
[61.]
J.C. Melby.
Diagnosis and treatment of primary aldosteronism and isolated hypoaldosteronism.
Clin Endocrinol Metab, 14 (1985), pp. 977-995
[62.]
E.L. Bravo, R.C. Tarazi, H.P. Dustan.
The changing spectrum of primary aldosteronism.
Am J Med, 74 (1983), pp. 641-651
[63.]
P.W. Lins, V. Anson.
Plasma aldosterone-plasma renin activity ratio: A simple test to identify patients with primary aldosteronism.
Act Endocrinol, 113 (1986), pp. 564-570
[64.]
T.J. McKenna, S.J. Sequera, A. Hefernan, J. Chambers, S. Cunninghann.
Diagnosis under random conditions of all disorders of the renin-angio- tensin-aldosterone acces incluiding primary hyperaldosteronism.
J Clin Endocrinol Metab, 73 (1991), pp. 952-957
[65.]
M.H. Weinberger, N.S. Fineberger.
The diagnosis of primary aldosteronism and separation of two major subtypes.
Arch Intern Med, 153 (1993), pp. 2125-2129
[66.]
C. Hambling, R.T. Junt, M.C.K. Browning, A. Gunn, J.M. Anderson.
Primary hyperaldosteronism: evaluation of procedures for diagnosis and treatment.
Q J Med, 86 (1993), pp. 392-393
[67.]
A.H. Shamma, J.W. Goddard, S.C. Sommers.
A study of the suprarrenal status in hypertension.
J Chronic Dis, 8 (1958), pp. 587-595
[68.]
C.K. Tang, C.F. Gray.
Adrenocortical neoplasms: prognosis and morphology.
Urology, 5 (1975), pp. 691-695
[69.]
M. Sullivan, M. Boileau, C.V. Hodges.
Suprarrenal cortical carcinoma.
J Urol, 120 (1978), pp. 660-665
[70.]
D.R. King, E.E. Lack.
Suprarrenal cortical carcinoma: a clinical and pathologic study of 49 cases.
Cancer, 44 (1979), pp. 239-244
[71.]
C. Tang, G. Cray.
Adrenocortical neoplasms. Prosnosis and morphology.
Urology, 5 (1975), pp. 691-695
[72.]
P.M. Copeland.
The incidentally discovered suprarenal mass.
Ann Intern Med, 98 (1983), pp. 940-945
[73.]
D.A. Bitter, D.S. Ross.
Incidentally discovered suprarrenal mass.
Am J Surg, 158 (1989), pp. 159-161
[74.]
R.A. Printz, M.G. Brooks, R. Churchill, J.L. Graner, A.M. Lawerence, E.S. Paloyan, et al.
Incidental asyntomatic suprarrenal masses detected by computed tomographic scanning: is operation requiered.
JAMA, 248 (1982), pp. 701-704
[75.]
R.L. Katz, A. Shirhoda.
Diagnostic approach to incidental suprarrenal nodules in the cancer patients: results of a clinical, radiologic and fineneele aspiration study.
Cancer, 55 (1985), pp. 1995-2000
[76.]
E.M. Remer, R.M. Weinfeld, G.M. Glazer, L.E. Quint, I.R. Francis, M.D. Gross, et al.
Hyperfunctioning and non-hyperfunctioning benign suprarrenal cortical lesions: characterization and comparison with MR imaging.
Radiology, 171 (1989), pp. 681-685
[77.]
P.D. Peppercorn, A.B. Grossman, R.H. Reznek.
Imaging of incidentally discovered suprarrenal masses.
Clin Endocrinol (Oxf, 48 (1998), pp. 379-388
[78.]
J.E. Lee, D.B. Evans, R.C. Hickey, S.I. Sherman, R.F. Gagel, M.C. Abbruzzese, et al.
Unknown primary cancer presenting as a suprarrenal mass: frequency and implications for diagnostic evaluation of suprarrenal incidentaloma.
Surgery, 124 (1998), pp. 1115-1122
[79.]
J.P. McGahan.
Suprarrenal gland: MR imaging.
Radiology, 166 (1988), pp. 284-285
[80.]
A. Oliva, B. Duarte, R. Hammadeh, L. Glosh, R.J. Baker.
Myelolipoma and endocrine dysfunction.
Surgery, 103 (1988), pp. 711-715
[81.]
A.A. Kasperlik-Zalusk, B. Migdalaska, W. Jeske, T. Tollozko, R. Szamowska, H. Snochowskc, et al.
Incidentally found suprarrenal tumours: Results of investigation of the pituitary suprarenal axis.
Endokrynol Polska, 43 (1992), pp. 322-329
[82.]
K.M. Cyran, P.J. Kenney, D.E. Mernel, I. Yacouib.
Suprarrenal myelolipoma.
Am J Roentgenol, 166 (1996), pp. 395-400
[83.]
Y. Tsushima.
Different lipid contents between aldosterone-producing and nonhyperfuncitoning adrenocortical adenomas: in vivo measurement using chemical-shiff magnetic resonance imaging.
J Clin Endocrinol Metab, (1994), pp. 1759-1762
[84.]
D. Fontana, F. Porplglia, P. Destefanis, C. Fior, C. Ali, M. Terzolo, et al.
What is the role of ultrasonography in the follow-up of suprarrenal incidentaloma?.
Urology, 54 (1999), pp. 612-616
[85.]
M.D. Gross, B. Shapiro, I.R. Francis, G.H. Glazer, R.L. Bree, M.A. Arcomano, et al.
Scintigraphic evaluation of clinically silent suprarrenal masses.
J Nucl Med, 35 (1994), pp. 1145-1152
[86.]
S. Bardet, V. Rohmer, A. Murat, C. Guillemot, R. Marechaud, M. Chupin, et al.
131-I-?-iodometyl norcholesterol scintigraphy: an assesment of its role in the investigation of adrenocortical incidentalomas.
Clin Endocrinol (Oxf, 44 (1996), pp. 587-596
[87.]
W.H. Beierwaltes, M.F. Sturman, R.Y. Ung, R.D. Ice.
Imaging functional nodules of the suprarrenal glands with 131I-19-iodocholesterol.
J Nucl Med, 15 (1974), pp. 246-249
[88.]
J. Salmerón de Diego, J.P. Domínguez Montero, I. Pato Castel, A. García Almansa, E. Caviola Mutazzi, J.M. Palacios Mateos.
Adenoma suprarrenal funcionante sin síndrome de Cushing.
Endocrinología, 25 (1978), pp. 143-147
[89.]
M. Reincke, J. Nieke, G.P. Krestin, W. Saeger, B. Allolio, W. Wienkelmann.
Preclinical Cushing’s syndrome in suprarrenal “incidentalomas” comparison with suprarrenal Cushing’s syndrome.
J Clin Endocrinol Metab, 75 (1992), pp. 826-832
[90.]
A. Virkkale, M. Valimaki, R. Relkone, K. Huikuri, A. Kahri, L. Kivisaari, et al.
Endocrine abnormalities in patients with suprarrenal tumours incidentally discovered on computed tomography.
Acta Endocrinol, 121 (1989), pp. 67-72
[91.]
S. Kobayashi, T. Seki, K. Nonomura, T. Gotoh, M. Togashi, T. Koyanagi.
Clinical experience of incidentally discovered suprarrenal tumor with particular reference to cortical function.
Jour Urol, 10 (1993), pp. 8-12
[92.]
S. Bardet, V. Rohner, A. Murat, C. Guillemot, R. Marechaud, M. Chupin, et al.
131I-6?-lodomethylnorcholecterol scintigraphy: and assessment of its role in the investigation of adrenocortical incidentalomas.
Clin Endocrinol (Oxf, 44 (1996), pp. 587-596
[93.]
L. Barzon, C. Scaroni, N. Sonino, F. Fallo, M. Gregiamin, C. Macri, et al.
Incidentally discovered suprarrenal tumors: endocrine and scintigrafic correlates.
J Clin Endocrino Metaba, 83 (1998), pp. 55-62
[95.]
B.C. Yankaskas, E.V. Stars, M.B. Craven.
Delayed complications from fine-needle biopsies of solid masses of the abdomen.
Inter Radiol, 21 (1986), pp. 325-328
[96.]
M.K. Mody, E.A. Zazerooni, M. Korbikin.
Percutanelus CT guide biopsy of suprarrenal masses: immediate and delayed complications.
Journal Computer Asist Tomography, 19 (1995), pp. 434-439
[97.]
D.V. Schapira, A.R. Jarrett.
The need to consider survival, outcome, and expense when evaluating and treating patients with uknow primary carcinoma.
Arch Intern Med, 155 (1995), pp. 2050-2054
[98.]
A. Dwamena, R.T. Kloos, A.M. Fendrick, M.D. Groos, I.R. Francis, M.T. Korobkin.
Diagnostic evaluation of the suprarrenal incidentaloma: decision and cost-effectiveness analyses.
J Nucl Med, 39 (1998), pp. 707-712
[99.]
M.H. Saboorian, R.L. Katz, C. Charnsangavej.
Fine needle aspiration cytology of primary and metastatic lesions of the suprarrenal gland: a series of 188 biopsies with radiologic correlation.
Acta Cytol, 39 (1995), pp. 843-951
[100.]
M. Abecassis, M.J. McLoughin, B. Langer, J.E. Kudlow.
Serendipitous suprarrenal masses: prevalence, significance and management.
Am J Surg, 149 (1985), pp. 783-788
[101.]
R.A. Prinz, M.H. Brooks, R. Churchill, J. Graner, A.S.M. Lawrence, E.S. Paloyan, et al.
Incidental asymptomatic suprarrenal masses detected by computed tomographic screening. Is operation required?.
JAMA, 248 (1982), pp. 701-704
Copyright © 2001. Sociedad Española de Endocrinología y Nutrición
